Clinical Trials Sponsored by Janssen Scientific Affairs, LLC

Total 204 results

Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

Multiple Myeloma

United States
Janssen Scientific Affairs, LLC

Completed

A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)

Hepatosplenic T-Cell Lymphoma

United States
Janssen Scientific Affairs, LLC

Terminated

An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease (ADAPT)

Inflammatory Bowel Diseases

United States, Canada
Janssen Scientific Affairs, LLC

Completed

Sustainable Early Episode Clinic Study (SEEC) (SEEC)

Schizophrenia | Schizoaffective Disorder

United States
Janssen Scientific Affairs, LLC

Completed

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis (AWARE)

Arthritis, Rheumatoid

United States
Janssen Scientific Affairs, LLC

Completed

A Study to Assess the Validation and Mapping of the Suicide Ideation and Behavior Assessment

Suicidality

United States
Janssen Scientific Affairs, LLC

Completed

Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation

Atrial Fibrillation

United States
Janssen Scientific Affairs, LLC

Withdrawn

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

Pain | Chronic Low Back Pain | Chronic Back Pain | Osteoarthritis Pain In The Hip or Knee

United States
Janssen Scientific Affairs, LLC

Completed

Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants

Healthy

United States
Janssen Scientific Affairs, LLC

Completed

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (DEFINE)

HIV-1

United States
Janssen Scientific Affairs, LLC

Completed

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (DREaM)

Psychotic Disorders | Schizophrenia

United States, Brazil, Mexico
Janssen Scientific Affairs, LLC

Terminated

Multiple Myeloma Patient Registry

Multiple Myeloma

United States
Janssen Scientific Affairs, LLC

Completed

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

HIV Infections | Pregnancy | HIV

United States, Puerto Rico
Janssen Scientific Affairs, LLC

Completed

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability (REAAcT)

Prostate Cancer

United States
Janssen Scientific Affairs, LLC

Completed

A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir

Hepatitis C Virus

United States
Janssen Scientific Affairs, LLC

Completed

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

Schizophrenia

United States, Puerto Rico
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

Schizoaffective Disorder

United States, Ukraine, Bulgaria, India, Malaysia, Romania, South Africa, Philippines
Janssen Scientific Affairs, LLC

Completed

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

Schizophrenia | Bipolar Disorder

United States
Janssen Scientific Affairs, LLC

Recruiting

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Crohn Disease | Colitis, Ulcerative

United States
Janssen Scientific Affairs, LLC

Active, not recruiting

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Psoriasis

United States, Australia, Ukraine, Belgium, Taiwan, Spain, Austria, Colombia, Israel, Portugal, Slovenia, Japan, Canada, Greece, Korea, Republic of, Argentina, Chile, Netherlands, Sweden, Slovakia, Czechia, Mexico
Janssen Scientific Affairs, LLC

Completed

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

Multiple Myeloma

United States
Janssen Scientific Affairs, LLC

Available

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Multiple Myeloma
Janssen Scientific Affairs, LLC

Completed

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year (SEAVUE)

Crohn Disease

United States, Belgium, Korea, Republic of, Netherlands, Italy, United Kingdom, Canada, France, Australia, Bulgaria, Poland, Germany, Serbia, Czechia, Russian Federation, Spain, Brazil, Hungary
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

HIV-1

United States
Janssen Scientific Affairs, LLC

Terminated

A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation (QUANTUM AF)

Atrial Fibrillation

United States
Janssen Scientific Affairs, LLC

Approved for marketing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Advanced Cancers and FGFR Genetic Alterations
Janssen Scientific Affairs, LLC

Completed

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) (FIRST)

Schizophrenia

United States
Janssen Scientific Affairs, LLC

Completed

Velcade (Bortezomib) Consolidation After Transplant (VCAT)

Multiple Myeloma

Australia, China, Korea, Republic of
Janssen Scientific Affairs, LLC

Completed

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Hypertension | Diabetes Mellitus, Type 2

United States, Puerto Rico
Janssen Scientific Affairs, LLC

Completed

An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (GALAXY)

Hepatitits C

United States
Bayer
Janssen Scientific Affairs, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

Netherlands
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department (MERCURY PE)

Pulmonary Embolism

United States
Bayer
Janssen Scientific Affairs, LLC

Completed

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)

Thrombosis | Venous Thrombosis | Thromboembolism | Venous Thromboembolism | Pulmonary Embolism

Belgium, France, China, Switzerland, New Zealand, South Africa, Hungary, United States, Canada, Australia, Netherlands, Spain, Russian Federation, Austria, Mexico, Taiwan, Brazil, Czechia, Denmark, Germany, Israel, Italy, Korea, Republic... and more
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI)

Atrial Fibrillation | Percutaneous Coronary Intervention

United States, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Argentina, Mexico, Bulgaria, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic of, Australia, Canada, Netherlands, Denmark and more
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants

Healthy

United States
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (BOX-DVT)

Venous Thrombosis

Belgium
Bayer
Janssen Scientific Affairs, LLC

Completed

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France (BROTHER)

Atrial Fibrillation

France
Bayer
Janssen Scientific Affairs, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

Sweden
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (XASSURE)

Stroke

China
Bayer
Janssen Scientific Affairs, LLC

Completed

Use of Direct Oral Anticoagulants in UK

Stroke

United Kingdom
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (VENTURE-AF)

Atrial Fibrillation

United States, France, United Kingdom, Belgium, Germany
Bayer
Janssen Scientific Affairs, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication (SAFARI)

Atrial Fibrillation

France
Bayer
Janssen Scientific Affairs, LLC

Completed

Dose-confirmatory Bridging Study in Total Knee Replacement

Venous Thromboembolism

Japan
All4Cure
Janssen Scientific Affairs, LLC

Recruiting

Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

Multiple Myeloma | Multiple Myeloma Without Mention of Remission

United States
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

Non-valvular Atrial Fibrillation (NVAF)

Japan
Janssen Scientific Affairs, LLC
Bayer

Completed

Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants

Pharmacokinetics | Healthy Participants | Bioavailability

United States
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)

Atrial Fibrillation

Belgium
Bayer
Janssen Scientific Affairs, LLC

Completed

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Deep Vein Thrombosis

Japan
Jonsson Comprehensive Cancer Center
Janssen Scientific Affairs, LLC

Recruiting

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8

United States
CirQuest Labs, LLC
Janssen Scientific Affairs, LLC

Unknown

Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease

Coronary Artery Disease | Heart Failure With Reduced Ejection Fraction

United States

3

Subscribe